Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Trading 12-23 12:40:26 EST

0.5462

-0.0228

-4.01%

High0.5600	Low0.5040	Vol125.25K
Open0.5510	D1 Closing0.5690	Amplitude9.84%
Mkt Cap2.76M	Tradable Cap2.11M	Total Shares5.05M
T/O66.96K	T/O Rate3.25%	Tradable Shares3.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":0.5462,"timestamp":1734974011317,"preClose":0.569,"halted":0,"volume":125245,"delay":0,"floatShares":3856399,"shares":5049720,"eps":-2.636215,"marketStatus":"Trading","change":-0.0228,"latestTime":"12-23 12:40:26 EST","open":0.551,"high":0.56,"low":0.504,"amount":66959.383664,"amplitude":0.098418,"askPrice":0.56,"askSize":100,"bidPrice":0.5218,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.636215,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"adrRate":1,"exchange":"NASDAQ","adjPreClose":0.569,"preHourTrading":{"tag":"盘前","latestPrice":0.56,"preClose":0.569,"latestTime":"09:15 EST","volume":5151,"amount":3018.5452365,"timestamp":1734963323537},"postHourTrading":{"tag":"盘后","latestPrice":0.544,"preClose":0.569,"latestTime":"19:53 EST","volume":13251,"amount":7397.6512,"timestamp":1734742401167},"volumeRatio":0.065688},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2493423416","title":"Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2493423416","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493423416?lang=en_us&edition=fundamental","pubTime":"2024-12-21 00:17","pubTimestamp":1734711425,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals  said Friday it has priced a public offering of 15.1 million American Depositary Shares, along with Series F and Series G warrants to purchase an equal number of ADSs, at $0.45 per ADS for a total of $6.8 million in gross proceeds.One ADS represents one ordinary share of the company.The funds will be used for general corporate purposes, including research and development, Quoin Pharmaceuticals said.The offering is expected to close by Monday.Quoin Pharmaceuticals shares fell nearly 6% in recent trading.Price: 0.61, Change: -0.04, Percent Change: -5.69","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","EQR","QNRX","BK4215","BK4585"],"gpt_icon":0},{"id":"2492445374","title":"Quoin Pharmaceuticals prices 15.1M ADSs at 45c in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2492445374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492445374?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:30","pubTimestamp":1734705036,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares represented by 15...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-prices-15-1m-adss-at-45c-in-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-prices-15-1m-adss-at-45c-in-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2492244185","title":"Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2492244185","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492244185?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:20","pubTimestamp":1734704400,"startTime":"0","endTime":"0","summary":"ASHBURN, Va., Dec.  20, 2024  (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/20/3000658/0/en/Quoin-Pharmaceuticals-Announces-Pricing-of-6-8-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139","WRD","PHH"],"gpt_icon":0},{"id":"2492120515","title":"Quoin Pharmaceuticals announces FDA clearance to initiate QRX003 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120515","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492120515?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:11","pubTimestamp":1734613864,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announces FDA clearance to initiate a new additional Netherton Syndrome clinical study for QRX003. QRX003 is a topical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-clearance-to-initiate-qrx003-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-clearance-to-initiate-qrx003-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2492183264","title":"Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183264","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183264?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:18","pubTimestamp":1734527880,"startTime":"0","endTime":"0","summary":"Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/18/2999032/0/en/Quoin-Pharmaceuticals-Announces-Positive-Interim-Data-from-Two-Ongoing-Netherton-Syndrome-Clinical-Studies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGA","PHH","BK4139","WRD","QNRX"],"gpt_icon":1},{"id":"2490813222","title":"Quoin Pharmaceuticals files to sell 19.23M ordinary shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2490813222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490813222?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:25","pubTimestamp":1733952326,"startTime":"0","endTime":"0","summary":"Maxim Group is acting as the exclusive placement agent for this offering. Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-files-to-sell-19-23m-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-files-to-sell-19-23m-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2490902270","title":"Quoin Pharmaceuticals Annual Meeting Approves Key Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2490902270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490902270?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:00","pubTimestamp":1733868039,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. Quoin Pharmaceuticals Ltd. held its 2024 Annual General Meeting where shareholders approved...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-annual-meeting-approves-key-amendments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-annual-meeting-approves-key-amendments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2488971330","title":"ADRs End Higher; Quoin Pharmaceuticals Ltd. Climbs 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488971330","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488971330?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:31","pubTimestamp":1733261460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Tuesday, as the S&P/BNY Mellon index of American depositary receipts added 0.8% to 184.06.The European index increased 0.6% to 168.77. The Asian index rose 1.1% to 236.87. The Latin American index increased 0.6% to 184.91, while the emerging-markets index added 1.1% to 382.50.Israel's Quoin Pharmaceuticals Ltd. was the biggest leader during the session, soaring 28% to 82 cents, and China-based Uxin Ltd. rocketed 21% to $5.11. 36Kr Holdings Inc., which is based in China, rounded out the top three leaders on Tuesday, with shares surging 18% to $3.91.Purple Biotech Ltd., based in Israel, posted the largest decline, plummeting 22% to $6.57, followed by shares of Hong Kong's iClick Interactive Asia Group Ltd., which plunged 19% to $4.80. Shares of Japan-based Lead Real Estate Co. Ltd. plunged 18% to $1.93.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2483397830","title":"QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483397830","media":"Zacks Small Cap Research","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483397830?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:00","pubTimestamp":1731409200,"startTime":"0","endTime":"0","summary":"U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations. Quoin Pharmaceuticals  provided a business update last week. The company implemented a number of measures during the quarter to move lead asset QRX003 forward. For instance, Quoin initiated testing of the safety and efficacy of QRX003 in a pediatric patient with Netherton Syndrome . NS is a rare inherited genetic disease for which there is currently no approved treatment or cure. This initiative addresses multiple QNRX’s objectives, including studying QRX003 in pediatric patient populations. Treating pediatric patients is important, as early treatment is critical to managing the disease. The company also commenced measures to expand clinical activities on QRX003 internationally. Separately, management raised its stake in QNRX shares, which we view as a positive indicator of its optimism about the company’s prospects.Two active late stag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnrx-international-sites-participating-qrx003-110000612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNRX","BK4139","BK4144","NORD","BK4590","NS"],"gpt_icon":1},{"id":"2482413648","title":"Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2482413648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482413648?lang=en_us&edition=fundamental","pubTime":"2024-11-09 14:01","pubTimestamp":1731132064,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Quoin Pharmaceuticals Ltd faces a sign...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-at-risk-of-nasdaq-delisting-amidst-financial-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-at-risk-of-nasdaq-delisting-amidst-financial-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","IE00B3QW5Z07.USD","QLD","QID","NDAQ","BK4588","TQQQ","IE00B64PRP62.GBP","BK4585",".IXIC","LU2210149790.SGD","NQmain","BK4112","BK4139","QNRX","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU2095319765.USD","SQQQ","MNQmain"],"gpt_icon":0},{"id":"2482755438","title":"Promising Developments and Financial Stability Propel Quoin Pharmaceuticals’ Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2482755438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482755438?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:35","pubTimestamp":1731087330,"startTime":"0","endTime":"0","summary":"Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Quoin Pharmaceuticals (QNRX). Naz Rahman has given his Buy rating due to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-and-financial-stability-propel-quoin-pharmaceuticals-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-and-financial-stability-propel-quoin-pharmaceuticals-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX"],"gpt_icon":0},{"id":"2481852139","title":"Quoin Pharmaceuticals Ltd reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481852139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481852139?lang=en_us&edition=fundamental","pubTime":"2024-11-08 01:20","pubTimestamp":1731000057,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd reports results for the quarter ended in September 30 - Earnings Summary  Quoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of 47 cents per share for the q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME3BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"gpt_icon":0},{"id":"2481907792","title":"Quoin Pharmaceuticals GAAP EPS of -$0.47 misses by $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2481907792","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481907792?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:26","pubTimestamp":1730985996,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals press release (NASDAQ:QNRX): Q3 GAAP EPS of -$0.47  misses by $0.01. Quoin had approximately $10.3 million in cash, cash equivalents and marketable securities as of Sept. 30, 2024. This is expected to fund the Company’s operations into late 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4260613-quoin-pharmaceuticals-gaap-eps-of-0_47-misses-0_01","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QNRX"],"gpt_icon":0},{"id":"2481904310","title":"Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904310","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904310?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:06","pubTimestamp":1730984782,"startTime":"0","endTime":"0","summary":"Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41805404/quoin-had-approximately-10-3m-in-cash-cash-equivalents-and-marketable-securities-as-of-sept-30-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2481904345","title":"Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904345","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904345?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:05","pubTimestamp":1730984739,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41805389/quoin-pharmaceuticals-q3-2024-gaap-eps-0-47-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"gpt_icon":0},{"id":"2481901488","title":"Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901488?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"Further Expansion of International Reach for Netherton Syndrome Clinical Trials. Significant Insider Share Purchases by the Entire Management Team. ASHBURN, Va., Nov. 07, 2024  -- Quoin Pharmaceuticals Ltd.  , a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024.-- Peeling Skin Syndrome  Study: In August, Quoin announced the planned. initiation of an investigator-led clinical study in New Zealand for. QRX003 in pediatric patients with Peeling Skin Syndrome. This rare. genetic condition currently has no approved treatments or cures. The. first clinical site and patient have been identified, and Quoin is. actively evaluating additional clinical sites in other countries.-- Insider Share Purchases: In September, Quoin's CEO, COO and CFO made. -- Netherton Syndrome Clinical Trials Expansion:","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WRD","BK4139","QNRX"],"gpt_icon":0},{"id":"2481250949","title":"Quoin initiates clinical testing of QRX003 in pediatric NS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481250949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481250949?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:15","pubTimestamp":1730812551,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that it has initiated the testing of the safety and efficacy of QRX003 in a young child with Netherton Syndr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-initiates-clinical-testing-of-qrx003-in-pediatric-ns-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-initiates-clinical-testing-of-qrx003-in-pediatric-ns-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4144","BK4139","QNRX","NS","BK4590"],"gpt_icon":0},{"id":"2481062585","title":"Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2481062585","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481062585?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with Potent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974879/0/en/Quoin-Pharmaceuticals-Initiates-Clinical-Testing-of-Lead-Product-in-Pediatric-Netherton-Syndrome-Patient.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4144","BK4590","BK4139","NS"],"gpt_icon":1},{"id":"2480696750","title":"Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480696750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480696750?lang=en_us&edition=fundamental","pubTime":"2024-11-01 04:05","pubTimestamp":1730405100,"startTime":"0","endTime":"0","summary":"ASHBURN, Va., Oct.  31, 2024  (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2973023/0/en/Quoin-Pharmaceuticals-to-Announce-Third-Quarter-2024-Financial-Results-on-Thursday-November-7-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":1},{"id":"2477335897","title":"BRIEF-Quoin Pharmaceuticals Announces Further International Expansion Of Ongoing Clinical Trials For Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2477335897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477335897?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:14","pubTimestamp":1729599272,"startTime":"0","endTime":"0","summary":"Oct 22  - Quoin Pharmaceuticals Ltd   :   * QUOIN PHARMACEUTICALS ANNOUNCES FURTHER INTERNATIONAL EXPANSION OF ONGOING CLINICAL TRIALS FOR NETHERTON SYNDROME   * QUOIN PHARMACEUTICALS LTD - EXPANDS NETHERTON SYNDROME STUDIES TO UK   * QUOIN PHARMACEUTICALS LTD - PREPARING TO OPEN ADDITIONAL SITES IN WESTERN AND EASTERN EUROPESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX","ETH"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.1405},{"period":"1month","weight":-0.0905},{"period":"3month","weight":0.0675},{"period":"6month","weight":-0.0709},{"period":"1year","weight":-0.8639},{"period":"ytd","weight":-0.884}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.110793},{"month":2,"riseRate":0,"avgChangeRate":-0.363342},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.207129},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.200377},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.086228},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.122896},{"month":7,"riseRate":0.666667,"avgChangeRate":0.046056},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.164394},{"month":9,"riseRate":0,"avgChangeRate":-0.26963},{"month":10,"riseRate":0.333333,"avgChangeRate":0.108579},{"month":11,"riseRate":0.25,"avgChangeRate":-0.186675},{"month":12,"riseRate":0,"avgChangeRate":-0.183713}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction